FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2735068920> ?p ?o ?g. }

• W2735068920 endingPage "2503" @default.
• W2735068920 startingPage "2494" @default.
• W2735068920 abstract "Background and Purpose— Evidence from the real-world setting complements evidence coming from randomized controlled trials. We aimed to summarize all available evidence from high-quality real-world observational studies about efficacy and safety of nonvitamin-K oral anticoagulants compared with vitamin-K antagonists in patients with atrial fibrillation. Methods— We searched PubMed and Web of Science until January 7, 2017 for observational nationwide or health insurance databases reporting matched or adjusted results comparing nonvitamin-K oral anticoagulants versus vitamin-K antagonists in patients with atrial fibrillation. Outcomes assessed included ischemic stroke, ischemic stroke or systemic embolism, any stroke or systemic embolism, myocardial infarction, intracranial hemorrhage, major hemorrhage, gastrointestinal hemorrhage, and death. Results— In 28 included studies of dabigatran, rivaroxaban, and apixaban compared with vitamin-K antagonists, all 3 nonvitamin-K oral anticoagulants were associated with a large reduction of intracranial hemorrhage (apixaban hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.31–0.63; dabigatran HR, 0.42; 95% CI, 0.37–0.49; rivaroxaban HR, 0.64; 95% CI, 0.47–0.86); similar rates of ischemic stroke and ischemic stroke or systemic embolism (apixaban HR, 1.05; 95% CI, 0.75–1.19 and HR, 1.08; 95% CI, 0.95–1.22 / dabigatran HR, 0.96; 95% CI, 0.80–1.16 and HR, 1.17; 95% CI, 0.92–1.50 / rivaroxaban HR, 0.89; 95% CI, 0.76–1.04 and HR, 0.73; 95% CI, 0.52–1.04, respectively); apixaban and dabigatran with lower mortality (HR, 0.65; 95% CI, 0.56–0.75 and HR, 0.63; 95% CI, 0.53–0.75, respectively); apixaban with fewer gastrointestinal (HR, 0.63; 95% CI, 0.42–0.95) and major hemorrhages (HR, 0.55; 95% CI, 0.48–0.63); dabigatran and rivaroxaban with more gastrointestinal hemorrhages (HR, 1.20; 95% CI, 1.06–1.36 and HR, 1.24; 95% CI, 1.08–1.41, respectively); dabigatran and rivaroxaban with similar rate of myocardial infarction (HR, 0.96; 95% CI, 0.77–1.21 and HR, 1.02; 95% CI, 0.54–1.89, respectively). Conclusions— This meta-analysis confirms the main findings of the randomized controlled trials of dabigatran, rivaroxaban, and apixaban in the real-world setting and, hence, strengthens their validity." @default.
• W2735068920 created "2017-07-21" @default.
• W2735068920 creator A5021615854 @default.
• W2735068920 creator A5030124716 @default.
• W2735068920 creator A5032256116 @default.
• W2735068920 creator A5038405190 @default.
• W2735068920 creator A5052877203 @default.
• W2735068920 creator A5076026606 @default.
• W2735068920 date "2017-09-01" @default.
• W2735068920 modified "2023-10-18" @default.
• W2735068920 title "Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation" @default.
• W2735068920 cites W1949360939 @default.
• W2735068920 cites W1961788044 @default.
• W2735068920 cites W1979423827 @default.
• W2735068920 cites W1981680557 @default.
• W2735068920 cites W1985967204 @default.
• W2735068920 cites W1998377301 @default.
• W2735068920 cites W2007820374 @default.
• W2735068920 cites W2010152642 @default.
• W2735068920 cites W2033083839 @default.
• W2735068920 cites W2042608661 @default.
• W2735068920 cites W2045352569 @default.
• W2735068920 cites W2063976695 @default.
• W2735068920 cites W2074206824 @default.
• W2735068920 cites W2081764758 @default.
• W2735068920 cites W2096246254 @default.
• W2735068920 cites W2097854437 @default.
• W2735068920 cites W2102255195 @default.
• W2735068920 cites W2109247912 @default.
• W2735068920 cites W2111947972 @default.
• W2735068920 cites W2118322677 @default.
• W2735068920 cites W2121403509 @default.
• W2735068920 cites W2121965454 @default.
• W2735068920 cites W2123251249 @default.
• W2735068920 cites W2123427884 @default.
• W2735068920 cites W2136489990 @default.
• W2735068920 cites W2137878797 @default.
• W2735068920 cites W2145530642 @default.
• W2735068920 cites W2159229357 @default.
• W2735068920 cites W2162508946 @default.
• W2735068920 cites W2165168223 @default.
• W2735068920 cites W2226726041 @default.
• W2735068920 cites W2404409120 @default.
• W2735068920 cites W2433454023 @default.
• W2735068920 cites W2442037294 @default.
• W2735068920 cites W2513537003 @default.
• W2735068920 cites W2520523056 @default.
• W2735068920 cites W2520573665 @default.
• W2735068920 cites W2521940263 @default.
• W2735068920 cites W2527161344 @default.
• W2735068920 cites W2554174230 @default.
• W2735068920 cites W2560688864 @default.
• W2735068920 cites W3004050106 @default.
• W2735068920 doi "https://doi.org/10.1161/strokeaha.117.017549" @default.
• W2735068920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28716982" @default.
• W2735068920 hasPublicationYear "2017" @default.
• W2735068920 type Work @default.
• W2735068920 sameAs 2735068920 @default.
• W2735068920 citedByCount "163" @default.
• W2735068920 countsByYear W27350689202017 @default.
• W2735068920 countsByYear W27350689202018 @default.
• W2735068920 countsByYear W27350689202019 @default.
• W2735068920 countsByYear W27350689202020 @default.
• W2735068920 countsByYear W27350689202021 @default.
• W2735068920 countsByYear W27350689202022 @default.
• W2735068920 countsByYear W27350689202023 @default.
• W2735068920 crossrefType "journal-article" @default.
• W2735068920 hasAuthorship W2735068920A5021615854 @default.
• W2735068920 hasAuthorship W2735068920A5030124716 @default.
• W2735068920 hasAuthorship W2735068920A5032256116 @default.
• W2735068920 hasAuthorship W2735068920A5038405190 @default.
• W2735068920 hasAuthorship W2735068920A5052877203 @default.
• W2735068920 hasAuthorship W2735068920A5076026606 @default.
• W2735068920 hasBestOaLocation W27350689201 @default.
• W2735068920 hasConcept C126322002 @default.
• W2735068920 hasConcept C127413603 @default.
• W2735068920 hasConcept C164705383 @default.
• W2735068920 hasConcept C207103383 @default.
• W2735068920 hasConcept C2776301958 @default.
• W2735068920 hasConcept C2776704044 @default.
• W2735068920 hasConcept C2778661090 @default.
• W2735068920 hasConcept C2778810321 @default.
• W2735068920 hasConcept C2779161974 @default.
• W2735068920 hasConcept C2780638905 @default.
• W2735068920 hasConcept C2780645631 @default.
• W2735068920 hasConcept C42219234 @default.
• W2735068920 hasConcept C44249647 @default.
• W2735068920 hasConcept C71924100 @default.
• W2735068920 hasConcept C78519656 @default.
• W2735068920 hasConceptScore W2735068920C126322002 @default.
• W2735068920 hasConceptScore W2735068920C127413603 @default.
• W2735068920 hasConceptScore W2735068920C164705383 @default.
• W2735068920 hasConceptScore W2735068920C207103383 @default.
• W2735068920 hasConceptScore W2735068920C2776301958 @default.
• W2735068920 hasConceptScore W2735068920C2776704044 @default.
• W2735068920 hasConceptScore W2735068920C2778661090 @default.
• W2735068920 hasConceptScore W2735068920C2778810321 @default.
• W2735068920 hasConceptScore W2735068920C2779161974 @default.

• next